Delos Wealth Advisors’s Axonics, Inc. Common Stock AXNX Stock Holding History

Delos Wealth Advisors’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-675	Closed	-$44K	–	487
2021 Q3	$44K	Hold	675	–	–	0.05%	59
2021 Q2	$43K	Buy	+675	New	+$39.8K	0.05%	56

Other funds holding AXNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Delos Wealth Advisors's AXNX Position: Q4 2021 in Review

Delos Wealth Advisors sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2021, closing a stake of 675 shares — an estimated $44K sold.

Delos Wealth Advisors first reported a position in AXNX in Q2 2021 and held it in 2 quarters. The position peaked at $44K in Q3 2021. 180 funds tracked by Wall St. Rank hold AXNX as of Q4 2021.

Delos Wealth Advisors reported no remaining Axonics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Delos Wealth Advisors sold 675 Axonics, Inc. Common Stock shares in Q4 2021, an estimated $44K.
Delos Wealth Advisors first reported a position in Axonics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
Delos Wealth Advisors's Axonics, Inc. Common Stock position peaked at $44K in Q3 2021.
180 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2021.

Based on Delos Wealth Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.